Overview

Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma. Study details include: * The study duration for each participant will be approximately 10 weeks. * The duration of IMP administration will be approximately 4 weeks.
Phase:
PHASE2
Details
Lead Sponsor:
AstraZeneca